ALX Oncology Holdings Inc. (NASDAQ:ALXO) Holdings Decreased by State Street Corp

State Street Corp lessened its stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 4.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 671,376 shares of the company’s stock after selling 34,171 shares during the period. State Street Corp’s holdings in ALX Oncology were worth $1,222,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Marshall Wace LLP raised its holdings in ALX Oncology by 423.0% during the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after purchasing an additional 514,133 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of ALX Oncology in the 2nd quarter worth $1,834,000. Los Angeles Capital Management LLC bought a new stake in shares of ALX Oncology in the 3rd quarter worth $469,000. Renaissance Technologies LLC lifted its holdings in shares of ALX Oncology by 87.2% in the second quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock valued at $2,642,000 after buying an additional 204,100 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in ALX Oncology during the second quarter valued at about $1,203,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

Insiders Place Their Bets

In other news, Director Rekha Hemrajani purchased 30,000 shares of ALX Oncology stock in a transaction that occurred on Monday, December 2nd. The stock was acquired at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the transaction, the director now owns 33,000 shares in the company, valued at $51,150. The trade was a 1,000.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 33.40% of the company’s stock.

ALX Oncology Trading Down 6.6 %

Shares of ALXO opened at $1.56 on Friday. The business’s 50-day moving average price is $1.52 and its 200 day moving average price is $2.90. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $82.28 million, a P/E ratio of -0.52 and a beta of 1.04. ALX Oncology Holdings Inc. has a 1-year low of $1.19 and a 1-year high of $17.83.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ALXO. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a report on Wednesday, December 18th. Finally, Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and reduced their target price for the stock from $12.00 to $2.00 in a report on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, ALX Oncology has a consensus rating of “Moderate Buy” and an average target price of $8.50.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.